Article

FDA to review STAAR toric ICL PMA

The FDA has given verbal notice indicating the agency’s intent to review STAAR Surgical Co.’s premarket approval (PMA) supplement regarding its toric ICL.

 

Monrovia, CA-The FDA has given verbal notice indicating the agency’s intent to review STAAR Surgical Co.’s premarket approval (PMA) supplement regarding its toric ICL.

The FDA will review the PMA at the Ophthalmic Devices Agency Panel meeting in February.

STAAR Surgical said it expects the federal register notice of the upcoming meeting to occur in early January.

Barry Caldwell, the company’s president and chief executive officer, gave a presentation to investors on the matter earlier this month.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.